Abstract:Background: Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare providers. Objective: This ongoing, observational, postapproval safety study evaluates clinical outcomes and disease progression in ivacaftor-treated patients using data from the US and the UK CF registries following commercial availability. Methods: Annual analyses compare ivacaftor-treated and untreated matched comparator patients for: risks of death, transplantation, hospitalisation, pulmonary exacerbation; prevalence of CF-related complications and microorganisms and lung function changes in a subset of patients who initiated ivacaftor in the first year of commercial availability. Results from the 2014 analyses (2 and 3 years following commercial availability in the UK and USA, respectively) are presented here. Results: Analyses included 1256 ivacaftor-treated and 6200 comparator patients from the USA and 411 ivacaftor-treated and 2069 comparator patients from the UK. No new safety concerns were identified based on the evaluation of clinical outcomes included in the analyses. As part of safety evaluations, ivacaftor-treated US patients were observed to have significantly lower risks of death (0.6% vs 1.6%, p=0.0110), transplantation (0.2% vs 1.1%, p=0.0017), hospitalisation (27.5% vs 43.1%, p<0.0001) and pulmonary exacerbation (27.8% vs 43.3%, p<0.0001) relative to comparators; trends were similar in the UK. In both registries, ivacaftor-treated patients had a lower prevalence of CF-related complications and select microorganisms and had better preserved lung function. Conclusions: While general limitations of observational research apply, analyses revealed favourable results for clinically important outcomes among ivacaftor-treated patients, adding to the growing body of literature supporting disease modification by CFTR modulation with ivacaftor. Eu pas registration number: EUPAS4270.

Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators

Exploring perceptions of and decision‐making about CFTR modulators

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy

Outcomes of Modulator Therapy Discontinued After Short‐Term Use in Adult Cystic Fibrosis

Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges

Scoring Abdominal Symptoms in People with Cystic Fibrosis

The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosis

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind

Respiratory Outcomes of Interrupted Modulator Therapies in Children With Cystic Fibrosis

Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform

The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation

Emerging Approaches to Monitor and Modify Care in the Era of Cystic Fibrosis Transmembrane Conductance Regulators

Adapting the cystic fibrosis care model: Perspectives from people with CF, caregivers, and members of CF care teams

Until it's done for everyone: the role of CFTR modulator label expansion

The gut-lung axis in the CFTR modulator era

Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis